GLP-1 may slow biological aging

Researchers at the University of California, San Francisco (UCSF) and the University of California, Los Angeles (UCLA) have conducted a study that suggests a popular GLP-1 weight loss medication may also slow down biological aging. The study, published in the journal Nature Communications, used data from the aging research database of the National Institute on Aging to analyze the effects of GLP-1 medications on aging. The researchers found that GLP-1 medications, which are commonly used to treat type 2 diabetes, may also have anti-aging effects by reducing inflammation and oxidative stress in the body. The study's lead author, Dr. Elizabeth Blackburn, a biologist at UCSF, notes that the findings are promising and warrant further research, but also emphasize that the study's results are based on observational data and should be interpreted with caution. The study's results are based on an analysis of data from over 4,000 people aged 50-79 who took GLP-1 medications for at least six months. The researchers found that those who took the medications had a 30% lower risk of aging biomarkers, such as telomere shortening and epigenetic changes, compared to those who did not take the medications. The study's results suggest that GLP-1 medications may be a potential therapeutic strategy for slowing down biological aging, but more research is needed to confirm the findings and understand the underlying mechanisms.